BioMarin Pharmaceutical (NYSE:BMRN)‘s stock had its “overweight” rating reaffirmed by research analysts at Piper Jaffray in a report released on Wednesday, Analyst Ratings News reports.
A number of other analysts have also recently weighed in on BMRN. Analysts at Leerink Swann raised their price target on shares of BioMarin Pharmaceutical from $76.00 to $78.00 in a research note to investors on Wednesday, November 20th. They now have an “outperform” rating on the stock. Separately, analysts at Jefferies Group cut their price target on shares of BioMarin Pharmaceutical from $86.00 to $83.00 in a research note to investors on Friday, October 25th. They now have a “buy” rating on the stock. Finally, analysts at Barclays raised their price target on shares of BioMarin Pharmaceutical from $70.00 to $75.00 in a research note to investors on Friday, October 25th. They now have an “overweight” rating on the stock. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $76.22.
BioMarin Pharmaceutical (NYSE:BMRN) traded up 0.28% on Wednesday, hitting $70.73. The stock had a trading volume of 962,883 shares. BioMarin Pharmaceutical has a 52-week low of $46.53 and a 52-week high of $80.67. The stock has a 50-day moving average of $66.06 and a 200-day moving average of $65.24. The company’s market cap is $10.059 billion.
BioMarin Pharmaceutical Inc (NYSE:BMRN) develops and commercializes pharmaceuticals for serious diseases and medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.